Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message

IF 0.9 Q3 Biochemistry, Genetics and Molecular Biology

Minerva Biotecnologica Pub Date : 2019-07-01 DOI:10.23736/S1120-4826.19.02556-4

A. Armandi, S. Bonetto, R. Pellicano, G. P. Caviglia, M. Astegiano, G. Saracco, D. Ribaldone

{"title":"Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message","authors":"A. Armandi, S. Bonetto, R. Pellicano, G. P. Caviglia, M. Astegiano, G. Saracco, D. Ribaldone","doi":"10.23736/S1120-4826.19.02556-4","DOIUrl":null,"url":null,"abstract":"Dupilumab is a human monoclonal antibody that has recently been approved for the treatment of mild-to-severe atopic dermatitis. Dupilumab inhibits the interleukin (IL)-4/IL-13 signalling by binding specific subunits of the receptors. IL-4 is involved in the regulation of both innate and adaptive intestinal immune system, thus its possible role in the pathogenesis of inflammatory bowel disease (IBD) has been investigated. Several polymorphisms of IL-4 have been found in patients with IBD. Furthermore, the crucial role of IL-4 has been demonstrated in Th2-driven models of colitis as well as in Th1-related models of this disease. Finally, many studies have shown the increased production of IL-4 in two models of experimental colitis: the dextran sulphate sodium – related colitis and the oxazolone-related colitis. In the latter, a dual antagonist of IL-4/IL-13 has proved to ameliorate the course of the disease. In conclusion, IL-4 antagonists might play a role in the treatment of IBD, especially in ulcerative colitis, which shows a classic pattern of Th2-related disease. and suggests","PeriodicalId":54738,"journal":{"name":"Minerva Biotecnologica","volume":"2 1","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Biotecnologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S1120-4826.19.02556-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 5

Abstract

Dupilumab is a human monoclonal antibody that has recently been approved for the treatment of mild-to-severe atopic dermatitis. Dupilumab inhibits the interleukin (IL)-4/IL-13 signalling by binding specific subunits of the receptors. IL-4 is involved in the regulation of both innate and adaptive intestinal immune system, thus its possible role in the pathogenesis of inflammatory bowel disease (IBD) has been investigated. Several polymorphisms of IL-4 have been found in patients with IBD. Furthermore, the crucial role of IL-4 has been demonstrated in Th2-driven models of colitis as well as in Th1-related models of this disease. Finally, many studies have shown the increased production of IL-4 in two models of experimental colitis: the dextran sulphate sodium – related colitis and the oxazolone-related colitis. In the latter, a dual antagonist of IL-4/IL-13 has proved to ameliorate the course of the disease. In conclusion, IL-4 antagonists might play a role in the treatment of IBD, especially in ulcerative colitis, which shows a classic pattern of Th2-related disease. and suggests

查看原文本刊更多论文

Dupilumab靶向白细胞介素4治疗炎症性肠病?基于翻译信息的假设

Dupilumab是一种人单克隆抗体，最近已被批准用于治疗轻度至重度特应性皮炎。Dupilumab通过结合特异性受体亚基抑制白细胞介素(IL)-4/IL-13信号传导。IL-4参与先天性和适应性肠道免疫系统的调节，因此其在炎症性肠病(IBD)发病机制中的可能作用已被研究。在IBD患者中发现了几种IL-4多态性。此外，IL-4在th2驱动的结肠炎模型以及该疾病的th1相关模型中发挥了关键作用。最后，许多研究表明，两种实验性结肠炎模型中IL-4的产生增加:葡聚糖硫酸钠相关性结肠炎和恶唑酮相关性结肠炎。在后者中，IL-4/IL-13的双重拮抗剂已被证明可以改善疾病的进程。总之，IL-4拮抗剂可能在IBD的治疗中发挥作用，特别是在溃疡性结肠炎中，这是一种典型的th2相关疾病。并建议

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minerva Biotecnologica 生物-生物工程与应用微生物

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Minerva Biotecnologica publishes scientific papers on biotechnology and molecular biology. Manuscripts may be submitted in the form of editorials, original articles, review articles, special articles and letters to the Editor. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work.